3M(TM) Filtek(TM) Supreme Flowable Composites for Class IV and Veneers
NCT07128589
Recruiting
This clinical study aims to evaluate the clinical performance of 3M™ Filtek™ Supreme Flowable Composite in class IV and veneer indication. Follow-ups of 7 days, 6, 12, and 24 months will be conducted following an Fédération Dentaire Internationale (FDI) modified score (2023). A minimum of 50 Class IV and 25 veneers will be included in the evaluation. Research data and pictures will be provided for each patient pre-op and at 7 days (baseline, 6 months, 12 months and 24 months. Evaluation will be... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/12/2025
Locations: NYU College Of Dentistry, New York, New York
Conditions: Dental Restoration, Dental Veneers
Register for Updates
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
NCT07100782
Recruiting
The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.
Gender:
FEMALE
Ages:
Between 21 years and 49 years
Trial Updated:
08/12/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Endometriosis, Pelvic Pain
Register for Updates
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
NCT07131631
Recruiting
This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100 evaluable at 6 months of follow-up. Enrollment will occur at up to eight centers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Minneapolis Heart Institute Foundation, Minneapolis, Minnesota +5 locations
Conditions: Heart Failure and Reduced Ejection Fraction, Functional Mitral Regurgitation
Register for Updates
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
NCT07093580
Recruiting
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
08/12/2025
Locations: ICON Clinical Research: Lenexa, Lenexa, Kansas +1 locations
Conditions: Healthy Participants
Register for Updates
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872
Recruiting
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Emerson Clinical Research Institute, Washington, District of Columbia +5 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates
The Effect of Multimodal Pain Regimen on Use of Narcotics After Rotator Cuff Tear Repair
NCT07076069
Recruiting
The goal of this clinical trial is to understand which group of pain control medications work best in adults after rotator cuff surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Montefiore Hutchinson Campus, Bronx, New York
Conditions: Rotator Cuff Repairs, Pain Management
Register for Updates
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #2037, Birmingham, Alabama +111 locations
Conditions: Weight Loss
Register for Updates
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
NCT07076407
Recruiting
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
08/12/2025
Locations: California Neuroscience Research, Sherman Oaks, California +2 locations
Conditions: Major Depressive Disorder
Register for Updates
Accelerated rTMS vs. Sham for Stroke Apathy
NCT07113067
Recruiting
Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To ad... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/12/2025
Locations: Medical University of South Carolina Brain Stimulation Lab, Charleston, South Carolina
Conditions: Apathy, Stroke, Stroke Sequelae, Stroke/Brain Attack, Stroke/ Cerebrovascular Accident (Ischemic or Hemorrhagic), Motivation, Abulia
Register for Updates
VIZ ACCESS HCM - Multi-Site Registry
NCT07103057
Recruiting
To describe the clinical, economic, and population characteristics of newly diagnosed, previously diagnosed, and suspected patients evaluated by Viz HCM. HCM is underdiagnosed in the community and AI algorithms have been developed as screening tools. However, it is not well understood how to best integrate AI screening tools and their potential impact.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Emory University, Atlanta, Georgia +2 locations
Conditions: Hypertrophic Cardiomyopathy
Register for Updates
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
NCT07109427
Recruiting
- The investigators propose a clinical trial to evaluate the impact of annual shared decision making for PSA screening, supported by system-level enhancements to promote evidence-based care: * Defined referral thresholds within the health maintenance reminder, aligned with clinical risk stratification per NCCN guidelines. * Enhanced clinical decision support (CDS) tools to reduce provider variation and ensure guideline-concordant screening and referral practices. * The goal is to reduce late-st... Read More
Gender:
MALE
Ages:
Between 40 years and 75 years
Trial Updated:
08/12/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Prostate Cancer, Cancer of the Prostate
Register for Updates
VK2735 for Weight Management Phase 3
NCT07104500
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #1037, Birmingham, Alabama +120 locations
Conditions: Weight Loss
Register for Updates